MINERALYS THERAPEUTICS, INC.
Cash Flow Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-241.1M | $-39.3M | $-32.2M | $-36.9M | $-43.3M | $-42.2M | $-48.9M | $-56.3M |
| Depreciation & Amortization | $5.0K | $6.0K | $13.0K | $15.0K | $16.0K | $15.0K | $15.0K | $11.0K |
| Depreciation | — | — | — | — | — | — | — | — |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $7.4M | $6.5M | $5.3M | $5.8M | $4.6M | $3.6M | $3.1M | $3.1M |
| Net Cash from Operating Activities | $-32.6M | $-39.5M | $-37.9M | $-28.9M | $-30.2M | $-45.5M | $-66.8M | $-50.2M |
| Investing Activities | ||||||||
| Capital Expenditures | — | — | $15.0K | $0 | $0 | $0 | $0 | $37.0K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-185.2M | $-44.9M | $-103.5M | $-150.5M | $-42.9M | $-92.9M | $83.6M | $79.6M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $243.3M | $24.3M | $96.7M | $295.2M | $9.8M | $189.3M | $90.0K | $-1.0K |
| Net Change in Cash | $25.5M | $-60.1M | $-44.7M | $115.8M | $-63.2M | $50.9M | $16.8M | $29.4M |
| Free Cash Flow | — | — | $-37.9M | $-28.9M | $-30.2M | $-45.5M | $-66.8M | $-50.2M |